Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H22N4O4 |
Molecular Weight | 406.4345 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C2C(NC=C2C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)C4=CC=CC=C4)=NC=C1
InChI
InChIKey=OKGPFTLYBPQBIX-CQSZACIVSA-N
InChI=1S/C22H22N4O4/c1-14-13-25(21(28)15-6-4-3-5-7-15)10-11-26(14)22(29)19(27)16-12-24-20-18(16)17(30-2)8-9-23-20/h3-9,12,14H,10-11,13H2,1-2H3,(H,23,24)/t14-/m1/s1
Molecular Formula | C22H22N4O4 |
Molecular Weight | 406.4345 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25203778Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12930892
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25203778
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12930892
BMS-378806 is a recently discovered small molecule HIV-1 inhibitor that blocks viral entrance to cells. The compound exhibits potent inhibitory activity against a panel of R5-(virus using the CCR5 coreceptor), X4-(virus using the CXCR4 coreceptor), and R5/X4 HIV-1 laboratory and clinical isolates of the B subtype (median EC50 of 0.04 microM) in culture assays. BMS-378806 is selective for HIV-1 and inactive against HIV-2, SIV and a panel of other viruses, and exhibits no significant cytotoxicity in the 14 cell types tested (concentration for 50% reduction of cell growth, >225 microM). BMS-378806 was proved to be specific for HIV-1, with no activity against HIV-2 or simian immunodeficiency virus. BMS-378806 is active against HIV-1 isolates irrespective of chemokine receptor preference. Mechanism of action studies demonstrated that BMS-378806 binds to gp120 and inhibits the interactions of the HIV-1 envelope protein to cellular CD4 receptors. BMS-378806 potently inhibited HIV-1 infection regardless of the particular chemokine receptor used.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12930892
Curator's Comment: BMS-378806 did not cross the blood–brain barrier to any appreciable extent.
Originator
Sources: http://adisinsight.springer.com/drugs/800017156
Curator's Comment: # Bristol-Myers Squibb
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. | 2003 Oct |
|
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. | 2003 Sep 16 |
|
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. | 2004 Apr 6 |
|
Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120. | 2005 May 7 |
|
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. | 2006 Oct |
|
Protection against HIV-envelope-induced neuronal cell destruction by HIV attachment inhibitors. | 2010 May |
|
Development of the next generation of HIV-1 integrase inhibitors: pyrazolone as a novel inhibitor scaffold. | 2010 Nov 15 |
|
Synthesis and biological evaluation of coumarin derivatives as inhibitors of Mycobacterium bovis (BCG). | 2012 Dec |
|
Inhibitors of HIV-1 attachment. Part 11: the discovery and structure-activity relationships associated with 4,6-diazaindole cores. | 2013 Jan 1 |
|
Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores. | 2013 Jan 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16142720
In rats, linear pharmacokinetics was observed between i.v. doses of 1 and 5 mg/kg and between p.o. doses of 5 and 25 mg/kg.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19534463
BMS-378806 demonstrated antiviral activity against HIV1 expressed in 293T cells (assessed as protection against viral M33 envelope infection in human U87 cells coexpressing CD4, CCR5 receptors after 72 hrs by luciferase reporter gene pseudoviral assay) with IC50 8 nM
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:27:38 GMT 2023
by
admin
on
Sat Dec 16 09:27:38 GMT 2023
|
Record UNII |
IMN5E6PLUK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
IMN5E6PLUK
Created by
admin on Sat Dec 16 09:27:38 GMT 2023 , Edited by admin on Sat Dec 16 09:27:38 GMT 2023
|
PRIMARY | |||
|
5495818
Created by
admin on Sat Dec 16 09:27:38 GMT 2023 , Edited by admin on Sat Dec 16 09:27:38 GMT 2023
|
PRIMARY | |||
|
357263-13-9
Created by
admin on Sat Dec 16 09:27:38 GMT 2023 , Edited by admin on Sat Dec 16 09:27:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |